# Stinging Salvation: Harnessing Scorpion Venom Peptides for Revolutionary Pain Relief

## TL;DR

Scorpion venom peptides offer a non-opioid approach to pain relief by targeting specific ion channels and reducing inflammation, with potential for treating neuropathic and cancer-related pain.

## Contribution

This review highlights the novel therapeutic potential of scorpion venom peptides and their engineered variants for pain management.

## Key findings

- Scorpion venom peptides like BmK-AGAP and SVHRP target ion channels and reduce inflammation in rodent pain models.
- Combining AGAP with lidocaine reduces the effective dose by half, enhancing therapeutic efficiency.
- Therapeutic levels of these peptides show low toxicity with an LD50 over 20 mg/kg.

## Abstract

Peptides from scorpion venom, mainly in species such as Olivierus martensii (formerly Olivierus martensii Karsch, often designated BMK) (BmK) and Tityus serrulatus from the Buthidae family, show real promise as painkillers that skip opioids altogether. They work by hitting specific ion channels and dialing down inflammation. This review gathers information on their molecular setups: disulfide-bridged types and those without, weighing in at 3 to 10 kilodaltons (kDa). Structural features include motifs stabilized by cysteines. In pain signaling, they block voltage-gated sodium channels (NaV) such as NaV1.7 and NaV1.8; take the BmK analgesic–antitumor peptide (BmK-AGAP) for example. Additionally, scorpion venom heat-resistant peptide (SVHRP) reduces microglia activity. Tests on rodents using formalin injections, acetic acid writhing, and chronic constriction injury (CCI) setups reveal pain relief that depends on dose and stacks up to morphine. Pairings like AGAP with lidocaine decrease the effective dose by half. In terms of safety, therapeutic levels have low-toxicity with a median lethal dose (LD50) over 20 mg/kg. Issues crop up with immune responses, unintended targets, and differences in venom batches. Clinical information remains thin, so gaps persist. Engineered versions could change the game for neuropathic pain, inflammatory conditions, and cancer-related discomfort. Standardization plus Phase I studies would help move this forward.